Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
May 1, 2025 7:00 AM EDT1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER
Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S.
Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand
Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H
Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER
Reiterating GAAP Profitability During H2... More



